3rd Antibody Drug Conjugates (ADC) Summit: From Target to Therapeutics

We are pleased to invite you to the 3rd Annual Antibody Drug Conjugates Summit: From Target to Therapeutics scheduled for May 17-18, 2018 in Barcelona, Spain.

This premier B2B event provides the appropriate platform to engage and discuss ideas with your fellow peers, while facilitating a professional atmosphere and environment for good company representation and development.

The summit will shed light on:

DISCOVERY, DEVELOPMENT & BIOANALYTICAL STRATEGIES TOWARDS NEXT GENERATION ADC:

  • Better understandable, more precise and new targets
  • Alternative scaffolds and new payloads
  • Optimized conjugation chemistry and stability
  • Improved therapeutic index

SUCCESSFUL TRANSLATION INTO CLINIC & CLINICAL PROGRESS:

  • ADC to treat tumours of the hematopoietic and lymphoid tissues
  • ADC to treat solid tumours
  • ADC to treat non-oncology diseases
  • ADC - immuno-oncology combinations
  • Bispecific - ADC combinations

ESTABLISHING ROBUST MANUFACTURING SUPPLY CHAINS

It is an honour and privilege to invite you to participate in this Summit. We look forward to welcoming you in Barcelona in May!

Who Should Attend:

Chief Executives, Vice Presidents, Directors, Department Heads, Leaders and Managers specialising in:

  • Drug Discovery
  • Clinical Development
  • Manufacturing/CMC
  • Protein Engineering
  • Molecular Biology
  • Medicinal Chemistry
  • Proteomics
  • Biomarkers
  • Cell Culture
  • Antibody & Biologicsv
  • Antibody-drug conjugates (ADCs)
  • Bioconjugates
  • Immunoconjugates
  • Monoclonal antibodies (mAbs)
  • Marine-based cytotoxins
  • Large molecule
  • Small-molecule drug conjugates
  • Peptide-drug conjugates
  • Nanoparticles / Nanobodies
  • Diabodies / Minibodies
  • PKPD
  • ADME
  • Toxicology
  • Analytical & Formulation
  • Assay Development
  • Bioanalysis
  • Translational Research
  • In Vitro
  • In Vivo
  • Cancer
  • Oncology
  • Haematology
  • Immunology
  • Antibody-based therapeutics
  • Biotherapeutics
  • Immunotherapeutics
  • Chemotherapeutics
  • Neurodegenerative Diseases

 

Speakers
Media partners
Partners